inhibition by increasing spiking or by elevating other aspects of synaptic transmission (although neither was seen in the time frame of the experiments conducted here). A compensation of this sort could impair global brain function and modestly elevate the proteostatic burden on neurons, resulting in a slow accumulation of cellular deficits that results in relatively widespread LB formation only late in life.
Although the deficit predicted by Nemani et al. should be widespread, it is possible that its impact is felt more by some neurons than others. Some of the most vulnerable neurons in PD-dopaminergic neurons in the substantia nigras pars compacta, noradrenergic neurons in the locus ceruleus, serotonergic neurons in the raphe nuclei, and cholinergic neurons in the basal forebrain nuclei (Jellinger, 1991) -have enormous axonal fields with orders of magnitude more synaptic terminals than most neurons (e.g., Matsuda et al., 2009) . Moreover, all of these neurons are spontaneously active in vivo, continually releasing transmitter in target structures like the striatum, cerebral cortex, and hippocampus (Baraban and Aghajanian, 1980; Chan et al., 2007; Vinogradova et al., 1980; Williams et al., 1984) . This sustained transmitter release is important to their targets, and all of these neurons have feedback systems at their terminals (e.g., autoreceptors that regulate the entry of calcium triggering exocytosis) to make sure that they are doing their job. It is not difficult to imagine that compromising the ability of these neurons to release transmitter might force them to work even harder than demanded by their normal role in brain, and that, after fifty or sixty years, they are left with axonal pathology (Galvin et al., 1999) and LBs.
The mechanisms underlying the brain response to systemic inflammation remain unclear. In this issue of Neuron, Serrats and colleagues demonstrate that two cell types that produce prostaglandins that act on the brain, perivascular and endothelial cells, have an unexpectedly complex interaction in regulating the timing and types of brain responses that occur.
During systemic inflammation, there is a stereotyped set of responses that are mediated by the brain. These include elevation of body temperature (fever), anorexia, reduction of pain thresholds, disruption of sleep cycles, and elevation of corticosteroids (Elmquist et al., 1997b) . The very fact that these responses are so stereotyped across many types of infection and that they are observed across the mammalian line indicates their adaptive value in fighting off infections. It has been known since the 1940s that inflammatory cells in the body elaborate hormones, originally called the ''endogenous pyrogen,'' that mediate these responses, and since the 1970s that proinflammatory cytokines such as interleukin-1 (IL-1), interleukin-6, and tumor necrosis factor a are responsible for this signaling. However, a key problem in understanding this cascade has remained: how does the brain receive the cytokine signals?
The blood-brain barrier (BBB) prevents most molecules in the bloodstream from having direct access to the brain. This is necessary, as the brain uses for internal signaling many of the same molecules that are used for intercellular communication in the bloodstream. Mixing the two signals would hopelessly muddle the signaling capabilities of the brain. But the BBB produces a problem: the brain must respond to many blood-borne signals, but has no direct access to them. This problem is solved in several ways.
Many hormones interact with the brain at circumventricular organs (Saper and Breder, 1994) . These are small bits of brain tissue such as the area postrema and organum vasculosum of the lamina terminalis, along the edges of the cerebral ventricles, that lack a BBB. Neurons in these regions can respond directly to blood-borne signals and then send their axons through a glial barrier into the remainder of the brain to relay the signals (sometimes using the same molecule as a neurotransmitter that they are monitoring in the blood).
Although early theories suggested this mechanism for immune signaling to the brain (Saper and Breder, 1994) , subsequent evidence has not supported this hypothesis. One of the most persuasive lines of evidence that the cytokines engage a different mechanism for signaling across the BBB has been that many of the brain effects of immune stimulation, including elevation of body temperature and corticosteroid responses (Elander et al., 2009; Zhang et al., 2003) , depend upon the generation of prostaglandins, particularly prostaglandin E2 (PGE2). Prostaglandins are lipids, which are capable of crossing the BBB and diffusing for short distances in the brain. Of course, humans have been using inhibitors of cycolooxygenase (COX), the prostaglandin synthetic enzyme, to prevent CNS immune responses (fever, hyperalgesia, etc.), for over 100 years, in the form of aspirin and the many other nonsteroidal anti-inflammatory drugs. But the circumventricular organs lack PGE2 receptors, which are deep within the brain (Oka et al., 2000) . Hence, the effects of immune signals on the brain must depend upon the production of prostaglandins, and the origin of those prostaglandins has become a central problem in neural-immune interactions.
In the late 1990s, two theories emerged for the origin of prostaglandins that affect the brain. One suggested that the endothelial cells of the blood vessels at the blood-brain interface, mainly small venules around the periphery of the brain, produced cyclo-oxygenase and prostaglandin E2 synthase, the enzyme cascade that generates PGE2, in response to immune stimulation with either lipopolysaccharide (LPS) or IL-1 (Laflamme et al., 1999; Matsumura et al., 1998) . The other theory suggested that perivascular cells (PVCs), which line the small venules, responded to low doses of the same immune stimulators (Elmquist et al., 1997a; Schiltz and Sawchenko, 2002) . PVCs are resident macrophages (Elmquist et al., 1997a) whose normal role is to endocytose and destroy invading organisms. Careful studies by Schiltz and Sawchenko showed that low doses of IL-1 and LPS cause expression of COX2 in the PVCs first, and then higher doses activate expression in the endothelial cells (Schiltz and Sawchenko, 2002) . However, Yamagata and colleagues found that PGE2 synthase was only found in the endothelial cells (Yamagata et al., 2001) , which indicated that the two cell types were probably engaged in a dialog in producing PGE2 and activating brain responses.
The new paper by Serrats and colleagues from the Sawchenko laboratory (Serrats et al., 2010 ) takes this story a step further, by demonstrating that this interaction actually is more complex than had previously been recognized, forming something like a dance that varies across both time and space and according to the stimulus that incites it. To dissect the roles of the PVCs and endothelial cells, they injected liposomes containing clodronate, a toxin that causes cell death, into the lateral cerebral ventricle. The liposomes were endocytosed by PVCs, which were then selectively depleted. This is where things got interesting. The intravenous administration of a low dose of IL-1 in PVC-depleted animals failed to elicit COX2 expression in endothelial cells. However a low dose of LPS caused an intensified activation of COX2 transcription in the endothelial cells. In other words, the PVCs were necessary for responses to low doses of IL-1, but for low doses of LPS the PVCs appeared to have an inhibitory effect on endothelial expression of COX2. Prostaglandin E2 synthase expression was elevated by both LPS and interleukin-1 in both endothelial cells and perivascular cells, in both groups of animals. Thus, because COX2 is the rate-limiting enzyme for prostaglandin synthesis in the small penetrating blood vessels of the brain, the increased expression of COX2 is likely to reflect an increased capacity by the tissue to produce PGE2 as a response to immune stimulation. As expected, PGE2 immunoreactivity was increased in PVCs, but not endothelial cells, with lowdose IL-1 challenge (and abrogated in the animals that were depleted of PVCs). However this same treatment enhanced endothelial-derived PGE2 immunoreactivity after low-dose LPS.
The Sawchenko group had previously shown that PGE2 synthesis in the ventrolateral medulla was necessary to activate A1 (noradrenergic) and C1 (adrenergic) neurons, whose projections to the paraventricular nucleus were required for elevation of expression of corticotrophin releasing hormone (CRH) and c-Fos after immune stimulation (Ericsson et al., 1997) . As expected, the activation of this pathway by low-dose IL-1 was blocked by depletion of PVCs, but the response to low-dose LPS was enhanced. The changes in expression of CRH and c-Fos (an immediate-early gene that signifies neuronal activation) in the paraventricular nucleus were mirrored by proportional changes in circulating adrenocorticotrophic hormone (ACTH) and corticosterone.
When they looked at fever responses in the same animals, the dance became an arabesque. Interleukin-1 produced a biphasic response in intact animals, with an initial hypothermia followed by a hyperthermic period. In animals that lacked PVCs, only the initial hypothermic response was lost, and as might be expected treatment with LPS yielded a vigorous fever response that was somewhat higher in the PVC-depleted group. Because the temperature elevation depends upon median preoptic neurons that respond to PGE2 via the EP3 receptor (Lazarus et al., 2007) , these results suggest that by 2 hr after injection there must be sufficient elevation of PGE2 in the IL-1-treated animals to cause the fever. On the other hand, loss of the early temperature depression, which also depends upon PGE2 (but for which the site of action and receptor subtype are not yet known), may indicate that the expression of PGE2 in the preoptic region is delayed in the animals lacking PVCs. This interpretation would be consistent with the effects of immune stimuli varying not just in the cell types that they activate, but also in the timing of that activation.
The elegant and nuanced pas de deux between the brain and the immune system has, of course, evolved to fight invasion by different microbial organisms. LPS is a component of the cell wall of Gram-negative organisms (such as E. coli and Salmonella typhimurium), and it is sensed by CD14 receptors that serve as an early warning component of the innate immune response. IL-1, by contrast, is a cytokine that is expressed by immune cells, including tissue macrophages (like PVCs), soon after an immune response is triggered, but would be expected to be elaborated during the first hour after the invasion of virtually any microbe. In life, LPS in the bloodstream during sepsis would therefore be detected by endothelial cells that express the CD14 receptor, which would activate perivascular microglia. These would in turn secrete IL-1, which would predominantly activate additional nearby perivascular cells and amplify their response, while simultaneously quieting the response of the endothelial cells.
Of course, all of this work was done with low doses of the stimuli, and the relationships could change as the dose of the stimulus increased. Also, as Serrats and colleagues point out, the nature of the signals interchanged by these two cell types and their intracellular signaling cascades remain a major frontier. However, as we unravel this story, it is clear that the nature of the brain response to immune stimuli depends upon the stimuli that are applied, their dosage, and on the types of responses that are measured, and in real-life infections, both stimuli and responses differ dynamically over time. The challenge for the future is to understand how this elaborate dance adapts mammals to ward off the challenges of microbial invasion.
